Presentation: 2B04

Fast, efficient and robust HTS with high quality and data content is a key prerequisite for keeping pace with the demands of modern drug discovery and with recent trends towards high quality / high content approaches for industrialized lead finding.

Novartis is addressing these issues with high flexibility in assay readout techniques and target portfolio on the NanoScreening platform. Within the same screening platform, confocal single molecule detection as well as more 'classical' assay readouts is applied according to particular demands of each biological target. Throughout several years of productive use we could achieve a significant experience with these technologies in order to strengthen the conscious application of either one of these different technologies. The most appropriate assay setup has to fulfill a number of criteria. The crucial criteria are stability of the assay readout in miniaturized format in terms of maximum sensitivity of assay at good (not perfect!!) Z and Z' values maintaining robust HTS performance concerning assay artifacts.

Several examples which highlight the strengths, weaknesses and pitfalls of the different technologies are shown in my presentation.

Close Window X